Introduction
GC induce growth arrest and apoptosis in immature lymphocytes and various malignancies of lymphoid origin (Thompson, 1994; Schwartzman and Cidlowski, 1994) , but the molecular basis of this clinically-relevant phenomenon is poorly understood. Like other GCregulated events, GC-induced cell death is mediated through, and requires, sucient levels of functional GC receptor (GR) (Powers et al., 1993; Ashraf and Thompson, 1993; Strasser-Wozak et al., 1995; Hala et al., 1996; Geley et al., 1996b) . However, whether transactivation or transcriptional repression of gene expression, or both, is required and/or sucient to activate the cell death pathway is not entirely clear. Evidence for a causal role of gene transactivation has been put forward in GC-induced rodent thymocyte (Schwartzman and Cidlowski, 1994) and mouse S49 thymoma (Chapman et al., 1996) apoptosis, while transrepression of gene expression has been suggested to underly this form of cell death in human Jurkat leukemia cells (Helmberg et al., 1995) . In any rate, the precise nature of the GC-regulated genes responsible for cell death induction is still unresolved, although several candidates have been suggested (reviewed in Geley et al., 1996a) .
Perhaps the most intriguing candidate for a central player in GC-induced apoptosis is the proto-oncogene c-myc, a sequence speci®c transcription factor that is expressed in proliferating hematopoietic cells (Grandori and Eisenman, 1997) . Like in several other leukemias and malignancies, c-myc is overexpressed in the CCRF-CEM human acute T-cell leukemia line and downregulated upon GC treatment (Yuh and Thompson, 1989; Ma et al., 1992) . Based on this fact, and upon transient transfection assays with c-myc expressing plasmids and experiments employing c-myc anti-sense oligonucleotides, Thulasi et al. (1993) proposed that c-myc downregulation may be the critical step in GC-induced apoptosis. According to this concept, GC-induced c-Myc depletion arrests the cells in the G1 phase of the cell division cycle which, in the putative presence of proliferative signals, represents a con¯icting signal that drives the cells to suicide. This compelling notion, however, contrasts with the hypothesis that c-Myc has inherent proapoptotic properties (Evan, 1997) , originally based on two seminal observations: First, c-Myc drives serumstarved ®broblasts into cell death , and second, it cooperates with bcl-2 in transforming cells, suggesting that this anti-apoptotic proto-oncogene neutralizes the inherent apoptotic function of c-Myc (Fanidi et al., 1992) .
To further address this issue, we generated stably transfected CCRF-CEM cells that express exogenous cmyc cDNA under the control of a tetracycline/ doxycycline-responsive promoter. Doxycycline-regulated induction of exogenous c-myc expression did not protect the cells from GC-induced cell death. In fact, c-myc overexpression slightly increased the sensitivity to GC-induced cell death, arguing against a critical role of c-myc downregulation by GC in this cell death pathway.
Results and discussion

Generation of CEM-C7H2 subclones with doxycycline-regulated expression of c-myc
To determine a possible functional role of c-myc downregulation in the GC-induced death pathway in CEM human leukemia cells, we generated stably transfected subclones of the GC-sensitive CEM-C7H2 line that allowed doxycycline-regulated expression of exogenous c-myc. For this purpose, we ®rst generated CEM-C7H2 subclones stably expressing the doxycycline-controllable synthetic`reverse' transcription factor, rtTA, from the chicken b-actin promoter. This promoter was selected because preliminary transient transfection experiments showed that it caused GCindependent, constitutive expression of reporter cDNAs in CCRF-CEM cells. From the resulting subclones, we selected one that showed signi®cant (up to 80-fold) induction of a tet operator-driven luciferase reporter gene upon treatment with tetracycline, or its analog, doxycycline (not shown). This subclone, termed CEM-C7H2 pEFrtTA -2C8, was subsequently stably transfected with the tet operator-driven human c-myc cDNA construct, ptetmyc, along with the hygromycin resistance encoding pKSpY3 selection plasmid. Two subclones, termed CEM-C7H2
tetmyc -B52 and D64, showing strong doxycycline-regulated expression of exogenous c-myc on the mRNA (Figure 1a ) and protein level (Figure 1b) , were used for further analyses.
Exogenous c-Myc increases sensitivity to serum withdrawal-induced apoptosis
To assess whether the induced c-Myc protein was functional, we cultured c-myc-transfected cells with or without doxycycline in low serum. Sensitivity to apoptosis induced by low serum is reportedly increased by c-Myc in ®broblasts . As shown in Figure 2 , reduction of fetal calf serum from 5% to 0.06% in the culture medium entailed low level apoptosis (about 10 ± 20% above background) in all tested cell lines. Induction of exogenous c-Myc markedly increased the sensitivity of our c-myctransfected subclones to serum withdrawal. In contrast, control cells (parental C7H2 cells and the C7H2-2C8 line that was transfected with the rtTA alone), showed no increased sensitivity to serum withdrawal a b Figure 1 (a) Doxycycline-induced c-myc mRNA expression in stably transfected CCRF-CEM leukemia cells. Parental C7H2-2C8 cells (stably transfected with the reverse transactivator construct as negative control) and 2C8 subclones B52 and D64 (stably transfected with the doxycycline-responsive c-myc construct) were cultured in the presence or absence of 300 ng/ml doxycycline (Doxy) for 24 h, and their RNA subjected to Northern blot analysis using 32 P-labeled cDNA probes for cmyc (top panel) and a-tubulin (bottom panel). The endogenous cmyc (endog. myc) migrates slower than the exogenous c-myc (exog. myc) due to dierent untranslated sequences. In the absence of doxycycline, there was only marginal expression of transgenic c-myc that was dramatically increased upon induction of the tetracycline-responsive promoter by doxycycline. (b) Doxycycline-induced c-Myc protein expression in stably transfected CCRF-CEM leukemia cells. Subclone D64 (stably transfected with the doxycycline-responsive c-myc construct) was cultured in the presence or absence of 300 ng/ml doxycycline (Doxy) for the time indicated and subjected to Western blot analysis using speci®c monoclonal antibodies against human cMyc and a-Tubulin Figure 2 Expression of transgenic c-myc increases sensitivity to serum withdrawal-induced apoptosis in CCRF-CEM leukemia cells. Parental C7H2-2C8 cells (stably transfected with the reverse transactivator construct as negative control) and 2C8 subclones B52 and D64 (stably transfected with the doxycycline-responsive c-myc construct) were preincubated for 24 h in the presence or absence of 300 ng/ml doxycycline, and then cultured in 5% (top panels) or 0.06% (bottom panel) fetal calf serum (FCS) for another 72 h. Cells were then subjected to apoptosis determination by the propidium iodide method (see Materials and methods). Shown is a representative example performed in triplicate. The percentages of apoptotic nuclei indicated above the sub-G1 marker have been calculated from triplicates with standard deviations below 3% c-Myc in GC-induced leukemia apoptosis M Lo Èffler et al upon doxycycline exposure. This indicated that the induced c-myc mRNA was translated into a functional protein, and further showed that c-Myc increased the sensitivity to serum withdrawal-induced apoptosis in these leukemia cells.
GC represses endogenous, but not doxycycline-regulated exogenous, c-myc expression GC has been reported to suppress c-myc mRNA steady-state levels in CCRF-CEM cells (Yuh and Thompson, 1989) . To address the possibility that dexamethasone might speci®cally interfere with doxycycline-regulated transgenic c-myc expression, Northern and Western blot analyses were performed with cells treated with doxycycline in the presence or absence of dexamethasone. Figure 3a documents that dexamethasone reduced endogenous c-myc mRNA in all cell lines to undetectable values, as expected (Yuh and Thompson, 1989) , but had no eect on doxycycline-induced transgenic c-myc expression compared with the a-tubulin`housekeeping' control (a-tubulin a b c Figure 3 (a) c-myc mRNA expression in GC-treated CCRF-CEM derivatives. Parental C7H2-2C8 cells (stably transfected with the reverse transactivator construct as negative control) and 2C8 subclones B52 and D64 (stably transfected with the doxycyclineresponsive c-myc construct) were cultured in the presence or absence of 300 ng/ml doxycycline for 24 h, followed by additional treatment with or without 10 77 M dexamethasone for 24 h. Subsequently, their RNA was subjected to Northern blot analysis using mRNA itself was somewhat repressed by dexamethasone re¯ecting a more general repressive eect of GC upon multiple transcription units as we have recently reported) (Hartmann et al., 1998) . Figure 3b demonstrates the ability of doxycycline to counteract the eect of dexamethasone on c-Myc protein levels in the stably transfected cell clones. Thus, GC-mediated downregulation of endogenous c-Myc was completely made up for by the doxycycline-regulated transgenic c-Myc.
Prevention of c-Myc downregulation does not protect CCRF-CEM leukemia cells from GC-induced apoptosis
To assess whether circumvention of GC-regulated cmyc downregulation by transgenic c-myc interfered with GC-induced apoptosis, we treated rtTA-transfected parental C7H2-2C8 cells (as control) and c-myc transfected C7H2-2C8 subclones B52 and D64 with dexamethasone in the presence or absence of doxycycline. As shown in Figure 3c , apoptosis was in no way prevented by induction of exogenous c-myc; to the contrary, the induced transgene accelerated the occurrence, and increased the percentage, of apoptotic cells, although in the absence of GC, it caused only marginally increased apoptosis. As expected, doxycycline had no eect on the rtTA-transfected parental C7H2-2C8 control cell line. Thus, the combined data strongly suggested that c-Myc downregulation by GC is not required for this form of apoptosis. Our conclusion that GC-induced downregulation of c-Myc is not required for GC-mediated cell-death in CCRF-CEM lymphoid leukemia cells contradicts a previous report suggesting that c-Myc downregulation by GC is the critical event leading to apoptosis in this system (Thulasi et al., 1993) . These authors showed that transient transfection by electroporation of CEM-C7 cells with c-myc expressing constructs attenuated dexamethasone-induced decrease in viable cells, and that antisense oligonucleotides to c-myc reduced viability more than corresponding sense oligonucleotides. The discrepancies might be due to the dierent technologies applied (transient transfection and antisense oligonucleotide technology versus doxycyclineregulated expression in stably-transfected cell lines), clonal divergence between the CCRF-CEM subclones used by the two groups, or other reasons. In support of our conclusion, Wood et al. (1994) reported that removal of GC from the medium after 36 h prevented apoptosis in CEM-C7A cells even though c-Myc protein remained repressed for another 24 h suggesting that sustained Myc downregulation does not entail cell death. Moreover, in P1798 mouse thymoma cells, GC-induced G1 cell cycle arrest as well as apoptosis elicited by the combined action of GC and serum withdrawal was also unaected by forced expression of c-myc (Rhee et al., 1995) . Interestingly, when c-myc was co-transfected with cyclin D3 (also downregulated by GC), a partial rescue from cell cycle arrest and apoptosis was observed.
Following the observation that c-myc overexpression in serum-starved ®broblasts causes cell death , it was proposed that c-Myc sensitizes cells to induction of apoptosis perhaps as a safeguard against cancer development. Numerous publications have, meanwhile, shown that c-myc overexpression indeed increases the sensitivity of various cell types to apoptosis induced, e.g., by growth factor withdrawal (Askew et al., 1991) , through membrane-bound death receptors (Hueber et al., 1997; JaÈ nicke et al., 1994; Klefstrom et al., 1994; Dong et al., 1997) , by T-and Blymphocyte antigen receptor activation (Shi et al., 1992; Bissonnette et al., 1994; Kaptein et al., 1996) , gamma irradiation (Chen et al., 1994) , transforming growth factor b1 (Selvakumaran et al., 1994) or chemotherapeutic compounds (Han et al., 1997; Dong et al., 1997) . Our study extends this list to apoptosis induced in a human lymphoblastic leukemia cell line either by serum starvation or GC.
What might be the mechanism by which c-Myc enhances GC-induced apoptosis? One c-Myc-induced death pathway leads to activation of the pro-apoptotic tumor suppressor p53 via p19 ARF (Zindy et al., 1998) . In CCRF-CEM cells, however, it seems unlikely that this pathway is involved, as both p53 alleles carry mutations interfering with normal p53 function (Geley et al., 1997a) . c-myc has been shown to sensitize cells for fas-induced apoptosis (Hueber et al., 1997) , but involvement of the fas system seems unlikely because dexamethasone and antibodies to fas apparently use dierent pathways upstream of the apoptosome as demonstrated by inhibitor studies. Thus, the caspase-8 inhibitor CrmA prevented Fas-, but not dexamethasone-induced apoptosis (Geley et al., 1997b) . Given the wide range of apoptotic stimuli that are enhanced by cmyc, it seems more likely that c-myc acts at an as yet unknown site in the distal eector pathway that is common to most, if not all, apoptotic pathways.
Materials and methods
Cell culture and reagents
All cell lines were grown in 5% CO 2 saturated humidity, at 378C in RPMI 1640 supplemented with 5 ± 10% bovine calf serum (HyClone, Logan, UT, USA), 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine. All other reagents were from Sigma (Vienna, Austria), unless indicated otherwise.
Plasmid constructs and stable transfectants
Plasmids pUHC172-1Neo and pUHD10-3 (Gossen and Bujard, 1992), pY3 (Blochlinger and Diggelmann, 1984) , pMV/mycER (Eilers et al., 1989) , pSTneoB (Katoh et al., 1987) and pbactinLuc (Miyazaki et al., 1989) were generously donated by Drs H Bujard, W Doppler, M Eilers, V Gagliardini and A Helmberg. pKSpY3 was generated by inserting the 2.2 kbp Moloney leukemia virus LTR-driven hydromycin cassette from plasmid pY3 into PstI/HindIII double-digested pBluescriptII-KS 7 (Stratagene, La Jolla, CA, USA). Plasmid pbrtTA was produced by linearizing pUHD172-1Neo with EcoRI, blunt-ending the EcoRI sites, digesting the plasmid with BamHI and subcloning the gelpuri®ed 1044 bp EcoRI ± BamHI fragment (containing the entire rtTA coding sequence) into pbactinLuc that was linearized with HindIII, blunt-ended, digested with BamHI, and gel-puri®ed to remove the luciferase containing fragment. In the resulting plasmid, the rtTA coding sequence is driven by the chicken b-actin promoter and polyadenylated using a human growth hormone polyadenylation signal. Plasmid ptetmyc was generated by ligating the mycER containing 2.4 kbp EcoRI fragment from pMV/mycER into the EcoRI linearized plasmid pUHD10-3. The resulting plasmid was c-Myc in GC-induced leukemia apoptosis M Lo Èffler et al digested with BamHI to remove the human estrogen receptor DNA binding domain, blunt-ended and religated.
To generate the constitutively rtTA-expressing cell line C7H2-2C8, logarithmically-growing CEM-C7H2 cells (Strasser-Wozak et al., 1995) were washed in phosphate buered saline (PBS: 136.89 mM NaCl, 10.14 mM Na 2 HPO 4 , 2.68 mM KCl and 1.76 mM KH 2 PO 4 , pH 7.4), pelleted at 300 g and resuspended at a density of 1610 7 cells/400 ml PBS. Cells were mixed with 75 mg ScaI-linearized pbrtTA together with 30 mg pSTneoB, incubated for 10 min on ice, and electroporated (Biorad Lab., Vienna, Austria) at 500 mF and 320 V. After electroporation, cells were placed on ice for another 10 min, diluted in 20 ml growth medium and seeded on 96-well¯at bottom plates. Selection of stably transfected cells was initiated 48 h after electroporation using 1 mg/ml G418 (bioactivity 70%, GIBCO ± BRL Life Technologies, Eggenstein, Germany). To produce stably transfected sublines with doxycycline-regulated c-myc expression, C7H2-2C8 cells were transfected as outlined above, but with 60 mg HindIIIlinearized ptetmyc together with 30 mg pKSpY3 and selected with 0.25 mg/ml hygromycin B (Boehringer Mannheim, Vienna, Austria).
Northern blot analysis
Northern blot analyses were performed as previously described (Geley et al., 1996b) . Brie¯y, total RNA was extracted by a single step extraction procedure, separated on formaldehyde-agarose gels, blotted onto nitrocellulose membranes and UV cross-linked (125m Joule, GS Gene Linker UV chamber, BioRad, Vienna, Austria). The ®lters were prehybridized to block nonspeci®c binding and hybridized to heat-denatured 32 P-labeled human c-myc (Eilers et al., 1989) or chicken a-tubulin (Cowan et al., 1983) cDNA probes, respectively. The washed blots were exposed to an Kodak X-ray ®lm with an amplifying screen at 7908C for 3 ± 24 h. Between hybridizations, blots were stripped with 0.1% SDS at 808C.
Western blot analysis
Cells were washed in PBS, lysed by boiling in SDS sample buer containing 10% b-mercaptoethanol for 2 min and subjected to SDS ± PAGE on a 10% gel, followed by transfer to nitrocellulose membranes. Membranes were blocked for 30 min with 5% nonfat dry milk in Tris-buered saline containing 1% Tween 20, followed by overnight incubation with a mouse monoclonal antibody against human c-Myc (Pharmingen Deutschland GmbH, Hamburg, Germany) in blocking buer at 48C. Horseradish peroxidase-conjugated secondary antibody (Amersham, Buckinghamshire, UK) was visualized using the Amersham ECL-system. Stripping and reprobing with antibody against a-tubulin (Oncogene Research, Cambridge, MA, USA) was performed as recommended in Amersham's ECL instructions.
Determination of apoptosis
Nuclear staining with propidium iodide in concert with forward/sideward scatter analysis (Nicoletti et al., 1991) was used for detection and quanti®cation of apoptosis. One ml of cells was centrifuged (5 min, 48C, 350 g), the supernatant discarded and the pellet stained with 750 ml fresh propidium iodide (50 mg/ml in 0.1% Triton X-100/0.1% sodium citrate). Subsequently, nuclei were subjected to apoptosis analysis in a FACScan (Becton Dickinson, San Jose, CA, USA) using forward/sideward scatter and¯uorescence intensity as parameters. Cell debris and small particles were excluded from further analyses based on forward/sideward scatter criteria as described (Sgonc and Wick, 1994) . Using these parameters, apoptotic nuclei appear smaller (lower forward scatter values) and more granulated (higher sideward scatter values) than living cells. Based on propidium iodide staining, nuclei in the sub-G1 marker window were considered to represent apoptotic cells (see marker in Figure 2 ).
Abbreviations
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